4CELL Therapies Spółka Akcyjna (KRS 0000692806, NIP 5252547574) is a Polish company, headquartered in Gliwice, Śląskie voivodeship. 4CELL Therapies operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since September 1, 2017. 4CELL Therapies's most recently reported net revenue was 0 PLN for 2025.
Negative equity
Negative equity in 3 of 4 available reporting years.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - 4CELL Therapies
Identity
- Name
- 4CELL Therapies Spółka Akcyjna
- Legal form
- SPÓŁKA AKCYJNA
- Founded
- September 1, 2017
- Registry status as of
- July 13, 2026
- Latest entry
- July 13, 2026
- Founding act
- 17.07.2017R., REP. A NR 4093/2017, RAFAŁ JAKUBASZEK NOTARIUSZ, KANCELARIA NOTARIALNA W WARSZAWIE
Articles of association history (9)
- July 17, 2017: 17.07.2017R., REP. A NR 4093/2017, RAFAŁ JAKUBASZEK NOTARIUSZ, KANCELARIA NOTARIALNA W WARSZAWIE
- September 9, 2019: 09.09.2019 R., REP. A NR 18679/2019, NOTARIUSZ MACIEJ MAKOWSKI, KANCELARIA NOTARIALNA W WARSZAWIE, ZMIANA: § 2 UST. 1, § 28 UST. 1
- June 23, 2020: 23.06.2020 R. - REP.A. NR 7939/2020, NOTARIUSZ MACIEJ MAKOWSKI, KANCELARIA NOTARIALNA W WARSZAWIE ZMIENIONO: §7 UST.2
- September 3, 2020: 03.09.2020 R., NOTARIUSZ MACIEJ MAKOWSKI, KANCELARIA NOTARIALNA W WARSZAWIE, REP. A NR 11499/2020 - ZMIENIONO: §7 UST.2
- March 24, 2021: 24.03.2021 R. - REP.A NR 4401/2021, NOTARIUSZ MACIEJ MAKOWSKI, KANCELARIA NOTARIALNA W WARSZAWIE - ZMIENIONO: §1, §41, §43
- August 18, 2021: 18.08.2021 R., REPERTORIUM A NR 12910/2021, NOTARIUSZ MACIEJ MAKOWSKI, , KANCELARIA NOTARIALNA W WARSZAWIE, REP. A NR 12910/2021 - ZMIENIONO:§ 38 STATUTU
- August 4, 2023: 04.08.2023 R., REP. A NR 8525/2023, NOTARIUSZ MACIEJ MAKOWSKI, KANCELARIA NOTARIALNA W WARSZAWIE ORAZ 18.10.2023 R. REP. A NR 11600/2023, NOTARIUSZ MACIEJ MAKOWSKI, KANCELARIA NOTARIALNA W WARSZAWIE - ZMIENIONO: §7 UST. 2
- December 19, 2025: 19.12.2025 R., REPERTORIUM A 9154/2025, NOTARIUSZ MACIEJ MAKOWSKI, KANCELARIA NOTARIALNA W WARSZAWIE; 22.12.2025 R., REPERTORIUM A 9233/2025, NOTARIUSZ MACIEJ MAKOWSKI, KANCELARIA NOTARIALNA W WARSZAWIE; ZMIENIONO: § 7 UST. 2 STATUTU.
- April 21, 2026: 21.04.2026 R. - REPERTORIUM A NR 3050/2026, NOTARIUSZ MACIEJ MAKOWSKI, KANCELARIA NOTARIALNA W WARSZAWIE - ZMIENIONO: §7 UST.2, §17, §18, §21 PKT 10), §32 UST.2, §35 STATUTU
Activities
Other activities
Address and contact
- Address
- UL. BOJKOWSKA, 59 C, 44-100, GLIWICE, POLSKA
- Voivodeship
- ŚLĄSKIE
- District
- GLIWICE
- Not disclosed in the registry
- Website
- WWW.4CELLTHERAPIES.COM
- E-delivery address
- AE:PL-61449-60062-HDUSJ-16
Risk and payment profile - 4CELL Therapies
Credibility rating
18.2 / 100
Very poor credibility
Insolvency risk
Very high
Significant formal threat
Closure risk
36
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/9 yrs
Board changes
4
4/9 yrs
PKD changes
0
0/9 yrs
Name changes
1
1/9 yrs
Data from 9 years of registry activity.
Credibility history
Payment reliability score from 2019–2025
Current: E (18/100)
Trend: deteriorating (-29.3 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2019–2025
Current: 0 PLN
Safe: 0 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - 4CELL Therapies
Founded
September 1, 2017
8 years in operation
Legal form
SPÓŁKA AKCYJNA
Registry: RejP
Headquarters
GLIWICE
ŚLĄSKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
2.5 M PLN
Shareholders
historical only
Board
1 person
Sup. board: 3
Filed years
4 years
2019–2025 · profitable: 1/4
Registry entries
52
latest: July 13, 2026
Risk signals
Revenue
0 PLN
2025
Net profit
-2.7 M PLN
2025
Assets
3.3 M PLN
2025
Equity
-2.7 M PLN
2025
EBITDA
-2.4 M PLN
2025
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - 4CELL Therapies.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
